Overview

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Teva Neuroscience, Inc.
Collaborator:
H. Lundbeck A/S
Treatments:
Dopamine
Dopamine Agents
Dopamine Agonists
Rasagiline